Skip to main content
BioArctic logo

BioArctic — Investor Relations & Filings

Ticker · BIOA ISIN · SE0010323311 LEI · 549300Y0OI2WVUNHLC33 ST Professional, scientific and technical activities
Open in API
Filings indexed 432 across all filing types
Latest filing 2024-02-06 Earnings Release
Country SE Sweden
Listing ST BIOA

About BioArctic

https://www.bioarctic.se/en/

BioArctic is a research-intensive biopharmaceutical company focused on developing disease-modifying treatments, biomarkers, and diagnostics for neurodegenerative diseases. The company's core strategy is based on its proprietary antibody technology, which develops unique treatments that target the misfolded and aggregated proteins considered to be the underlying cause of disorders such as Alzheimer's and Parkinson's disease. Through strategic partnerships with global pharmaceutical companies, BioArctic advances its innovative therapies from research through clinical development and commercialization, aiming to address significant unmet medical needs in neurology.

Recent filings

Filing Released Lang Actions
Försäljningen av Leqembi® uppgick till 1,1 miljarder yen under det fjärde kvartalet 2023
Earnings Release Classification · 1% confidence The document is titled "Pressmeddelande" (Press Release) and announces sales figures for Leqembi for Q4 2023, based on the partner Eisai's quarterly report. It explicitly states that Eisai published its quarterly report and provides a link to Eisai's financial documents. The document itself is a communication from BioArctic informing the market about the results reported by its partner, rather than being the comprehensive quarterly report (IR) or the initial earnings release (ER) itself, although it contains earnings-related data. Crucially, it also mentions that BioArctic's own annual report (bokslutsrapport) will be published later. Since this is a specific announcement regarding financial performance data derived from a partner's filing, and it is presented as a press release, it most closely aligns with an Earnings Release (ER) which typically contains key highlights, or potentially a Regulatory Filing (RNS) if it were less specific. Given the focus on the sales figures and royalty income for the period, ER is the most appropriate fit among the specific financial codes, as it serves as the company's immediate communication of period results, even if sourced externally. It is not a full Interim Report (IR) or Annual Report (10-K). Q4 2023
2024-02-06 Swedish
Sales of Leqembi® totaled 1.1 billion yen in the fourth quarter 2023
Earnings Release Classification · 1% confidence The document is explicitly labeled as a "Press release" and details the sales figures for a partnered drug (Leqembi) for the fourth quarter of 2023, issued by the partner company Eisai. It highlights key financial outcomes (sales amount and resulting royalty payment) and references the partner's full quarterly report and presentation material. This structure—a brief announcement of key financial results for a period—is characteristic of an Earnings Release (ER). It is not the comprehensive Annual Report (10-K) or the Interim Report (IR), as it only summarizes the partner's quarterly data relevant to BioArctic, and it explicitly points to the partner's full documents. It is also not an RPA because it is providing the core financial update, not just announcing the publication of a report. Q4 2024
2024-02-06 English
Declaration of Voting Results & Voting Rights Announcements 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document details a change in shareholding by 'Fjärde AP-fonden' in 'BioArctic AB'. It explicitly states the 'Reason for major shareholding notification' and provides the 'Before the transaction' and 'After the transaction' share quantities and resulting percentages (5.4% and 2.19%). This content directly corresponds to the definition of a Major Shareholding Notification, which is classified as 'MRQ'. The document is a formal notification of crossing a threshold or a significant change in ownership.
2024-01-25 English
Europeiska läkemedelsmyndighetens vetenskapliga rådgivande grupp kommer att diskutera ansökan om marknadsgodkännande för lecanemab
Regulatory Filings Classification · 1% confidence The document is a press release (indicated by "# **Pressmeddelande**") from BioArctic AB announcing that its partner Eisai's application for marketing authorization (MAA) for lecanemab is being discussed by the European Medicines Agency's (EMA) Scientific Advisory Group (SAG). It details regulatory timelines (EMA meeting in Q1 2024, potential EC decision in Q2 2024) and provides background on the drug and company collaborations. This type of announcement, focusing on regulatory progress and key business updates outside of routine financial reporting (like 10-K or ER), fits best under the general category for regulatory or significant business news that isn't explicitly covered by other codes like DIRS, DIV, or CAP. Since it is a formal announcement regarding regulatory steps for a product, and it is not a full financial report, a management discussion, or a transcript, the most appropriate classification is Regulatory Filings (RNS) as a general regulatory announcement, or potentially LTR if the focus was on legal proceedings, but here it is about regulatory approval processes. Given the context of regulatory updates that don't fit specific financial forms, RNS is the best fit, although it is a very specific type of regulatory update. It is not an Earnings Release (ER) or an Interim Report (IR). It is a formal announcement of regulatory activity.
2024-01-11 Swedish
The European Medicines Agency’s Scientific Advisory Group (SAG) to discuss the Marketing Authorisation Application for lecanemab
Legal Proceedings Report Classification · 1% confidence The document is explicitly titled "Press release" and announces that the European Medicines Agency's Scientific Advisory Group (SAG) will discuss the Marketing Authorisation Application (MAA) for lecanemab. It details regulatory timelines (Q1 2024 meeting, Q2 2024 decision expectation) and provides background on the drug and the companies involved (BioArctic and Eisai). This type of announcement, which communicates a specific, time-sensitive corporate event or regulatory milestone via a press release format, fits best under the general category for regulatory announcements that aren't formal financial reports (like 10-K or IR) or specific insider/dividend actions. Since it is a general announcement regarding regulatory progress and not a full report, the most appropriate classification is Regulatory Filings (RNS), which serves as a broad category for such corporate disclosures that don't fit the more specific financial or governance codes.
2024-01-11 English
Leqembi® approved for the treatment of Alzheimer’s disease in China
Regulatory Filings Classification · 1% confidence The document is titled "Press release" and announces the approval of Leqembi® in China. It details the drug's mechanism, clinical trial results (Clarity AD study), market launch plans, and the collaboration structure between BioArctic and Eisai. The text concludes with a statement indicating it is information the company is "obliged to disclose pursuant to the EU Market Abuse Regulation" and provides contact information for IR. This structure—a formal announcement of significant corporate/product news, often related to regulatory milestones or financial events, released via press wire—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since this is a specific, material announcement about a major regulatory event (drug approval) and market expansion, it is more specific than a general RNS. However, it is not a full financial report (10-K, IR) or a transcript (CT). It is a high-level announcement of results/events, which aligns best with an Earnings Release (ER) if it were quarterly results, but since it's a specific regulatory/commercial milestone announcement, and given the options, it functions as a material disclosure. In many databases, major press releases announcing key milestones that aren't strictly financial results are often categorized under the closest relevant category or as a general regulatory filing. Given the options, and recognizing this is a material disclosure outside of standard periodic financial reports, it fits best as a general regulatory announcement or an Earnings Release if we interpret 'Earnings Release' broadly to include major operational/regulatory news releases. Since it is a press release announcing a major regulatory approval and commercial update, and not a standard quarterly financial summary, 'RNS' (Regulatory Filings - general fallback) is the most appropriate category for a non-standard, material press release that doesn't fit ER, DIV, CAP, etc. However, if we consider the nature of the announcement (a major milestone announcement often released alongside or instead of quarterly updates), ER is sometimes used for significant news. Given the explicit mention of regulatory obligation and the press release format, RNS is the safest fallback for a material announcement that isn't a standard financial report.
2024-01-09 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.